Core Viewpoint - The article discusses the author's commitment to holding Business Development Companies (BDCs) despite the potential for an upcoming recession, indicating a belief in the resilience and long-term value of these investments [1]. Group 1: Investment Strategy - The author identifies as a buy-and-hold investor, focusing on quality over quantity in investment choices, particularly in dividend-paying stocks, BDCs, and REITs [2]. - The goal is to supplement retirement income through dividends within the next 5-7 years, targeting lower and middle-class workers to help them build quality investment portfolios [2]. Group 2: Analyst Disclosure - The author has a beneficial long position in specific BDC shares, namely ARCC and BXSL, indicating a personal investment stake in these companies [3]. - The article is presented as a personal opinion without compensation from the companies mentioned, emphasizing independence in analysis [3].

Core Viewpoint - Blackstone (BX) has experienced a significant decline in stock performance, down 14% year to date, underperforming the S&P 500's 0.4% fall, raising questions about its investment appeal [1][4]. Performance Summary - Blackstone's first-quarter 2025 results exceeded Zacks Consensus Estimates, with total assets under management (AUM) reaching $1.17 trillion, a 10% increase year over year, driven by $61.6 billion in inflows [5]. - As of March 31, 2025, Blackstone had $177.2 billion in undrawn capital available for investment, positioning the company to capitalize on market dislocations [9][11]. Challenges and Market Conditions - The company faces headwinds such as tighter credit markets, prolonged high interest rates, reduced deal activity in private equity and real estate, and concerns regarding exit opportunities [6][8]. - The ongoing uncertainty due to trade policies under the Trump administration has led to muted deal activities and caution in the IPO market [7][8]. Analyst Sentiment and Earnings Estimates - The Zacks Consensus Estimate for earnings has been revised downwards for 2025 and 2026 to $4.77 and $6.35, indicating growth rates of 2.8% and 33.1%, respectively [13]. - Blackstone's stock is trading at a price-to-tangible book (P/TB) ratio of 6.94X, significantly above the industry average of 3.47X, suggesting the stock is expensive [16][18]. Strategic Initiatives - Blackstone is focusing on key sectors such as digital infrastructure, energy, life sciences, and commercial real estate recovery, with growth opportunities in India and Japan [11]. - An alliance formed with Wellington and Vanguard aims to develop simplified multi-asset investment solutions, enhancing investor access to institutional-quality portfolios [12]. Investment Outlook - The combination of declining stock performance, premium valuation, and macroeconomic uncertainties raises concerns for investors [19]. - Despite challenges, Blackstone's deployable capital and expansion initiatives could act as growth catalysts, but a cautious investment approach is recommended until clearer recovery indicators emerge [20].

Group 1 - The core focus of the news is on President Donald Trump's visit to the Persian Gulf, aiming to secure business deals and strategic partnerships with Saudi Arabia, the UAE, and Qatar [3][5]. - Notable business leaders, including Elon Musk, Sam Altman, and Larry Fink, were present at the Saudi royal court to engage with Trump and Crown Prince Mohammed bin Salman [1][2]. - Saudi Arabia has pledged $600 billion in investments in the U.S., with potential commitments reaching up to $1 trillion, covering areas such as technology, defense, and artificial intelligence [5]. Group 2 - The U.S.-Saudi Investment Forum is a key event during Trump's visit, bringing together major investors from both nations to celebrate a long-standing partnership [8]. - The historical significance of the Saudi-U.S. relationship is highlighted, noting its strategic role over the past eight decades since the first meeting between King Abdulaziz and President Roosevelt [9]. - Trump's itinerary includes discussions on a possible civil nuclear program and expanded defense cooperation, which may relate to broader geopolitical dynamics in the region [5][9].

消息人士：黑石集团正在商谈收购新墨西哥公共服务公司东家TXN能源。谈判仍可能被推迟或出现波 折。 ...

黑石集团据悉正在谈判收购新墨西哥州 公用事业公司 TXNM。 ...

黑石集团据悉正在谈判收购新墨西哥州公用事业公司TXNM，黑石与TXNM的谈判仍有可能推迟或动 摇。（彭博） ...

Digital services provider TaskUs (TASK 17.59%) had a busy day on Friday. The company, which provides customer support and business process operations to other businesses, reported first-quarter earnings in the early morning -- and that wasn't the biggest news of the day. TaskUs is also going private in a deal financed by its co-founders and banking powerhouse Blackstone (BX -0.03%).The stock had gained 18.2% overnight as of 12:45 p.m. ET, trending higher across the morning session. Analyst-stumping earnings ...

据媒体最新透露的消息，其他随行的美国华尔街投资机构高管还包括来自黑石集团的共同创始人兼首席 执行官苏世民(SteveSchwarzman)、来自富兰克林邓普顿的珍妮·约翰逊，以及来自谷歌母公司Alphabet Inc.的首席财务官露丝·珀拉特(RuthPorat)。 智通财经APP获悉，据媒体报道，全球最大规模资管巨头贝莱德公司(BlackRock )的首席执行官拉里·芬 克、华尔街金融巨头花旗集团(Citigroup Inc.)首席执行官简·弗雷泽以及多位来自硅谷的美国科技巨头高 管们，将在下周随美国总统唐纳德·特朗普一起访问中东经济大国——沙特阿拉伯。 据媒体报道，这些来自华尔街和硅谷的高管们计划将于5月13日在利雅得的"沙美投资论坛"上发表重要 演讲。在论坛举办当日，特朗普将抵达沙特并预计会晤沙特王储穆罕默德·本·萨勒曼。 重返白宫的美国总统特朗普也将前往卡塔尔和阿联酋，这是其重新掌权以来的首次出访。他希望这些富 含油气资源的海湾国家加大对美国的投资并购买更多的美国制造与生产的各项重要产品。 据了解，来自美国老牌科技巨头IBM的首席执行官阿文德·克里希纳以及来自美国智能手机与汽车芯片 领军者高通公司(Q ...

智通财经5月6日电，贝莱德公司首席执行官拉里·芬克、花旗集团的简·弗雷泽，以及一些美国科技公司 的高层将随同美国总统唐纳德·特朗普下周访问沙特。这是特朗普就任总统以来首次预先安排的出访， 他还将访问卡塔尔和阿联酋。他希望石油和天然气资源丰富的海湾国家增加对美国的投资，购买更多美 国商品。其他将前往利雅得的美国企业高管包括Blackstone Inc.的史蒂夫·施瓦茨曼，富兰克林邓普顿的 珍妮·约翰逊，以及 Alphabet Inc.的露丝·波拉特。按计划他们将在5月13日的沙特-美国投资论坛上发 言。此次会议将涵盖能源、人工智能、先进制造和金融等议题。白宫AI和加密货币负责人大卫·萨克斯 将出席，当地知名人士包括沙特阿美首席执行官阿明·纳赛尔，以及沙特的能源、投资和财政大臣。特 朗普寻求增加1万亿美元来自沙特的投资和贸易，对阿联酋的期望也相当。 特朗普将访问沙特等中东三国 贝莱德、花旗等众多公司高管随行 ...

Group 1 - Elanco Animal Health announced the sale of future tiered royalties and commercial milestones related to Xdemvy for $295 million in cash, aimed at accelerating debt reduction [1] - The proceeds from the sale will help Elanco achieve a net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025 [1] - Elanco plans to repay portions of its outstanding term loans, which is expected to reduce interest expenses by approximately $10 million [2] Group 2 - Xdemvy, the first lotilaner-based product approved for human use, addresses Demodex blepharitis and is licensed to Tarsus Pharmaceuticals for exploration of human health applications [3] - The agreement covers tiered royalties on Xdemvy's U.S. net sales from April 2025 through August 2033 [3] - Elanco retains rights to all royalty payments on net sales outside the U.S. and any future human applications of lotilaner beyond ophthalmic solutions [4] Group 3 - Elanco is scheduled to release its Q1 2025 financial results, with analysts expecting adjusted earnings per share of 31 cents and sales of $1.21 billion [4] - The current stock price of Elanco is $9.75, which is below the 200-day moving average of $12.34, indicating potential bearish sentiment [6] - Recent trading saw Elanco's stock decrease by 1.03% to $9.65 [7]